CTNM — Q2 2026 Financial Report Analysis

Contineum Therapeutics is a clinical-stage biotech: a company testing experimental drugs in human trials with nothing yet approved to sell, so it has no product revenue and lives on the cash it has raised from investors. In the second quarter of 2026 (April–June) it lost $15.2 million, slightly less than the $16.0 million a year earlier. Research spending fell 10% to $12.7 million, but not because the company is doing less: a finished multiple sclerosis trial for its partnered drug PIPE-307 stopped generating bills, while its main bet, a 324-patient Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF, a scarring disease of the lungs), started to cost more. The company ended June with $236.6 million in cash and investments and says that lasts until mid-2029. The biggest news came after the quarter closed: on September 14 Johnson & Johnson reported that its Phase 2 depression trial of PIPE-307 missed its main goal.

At a glance

• $236.6 million in cash and investments at June 30, 2026, up from $175.5 million a year earlier because of a $93.0 million share sale in December 2025. Management says this funds the company through mid-2029, about a year past the expected end of the IPF trial.
• $27.8 million of cash used by operations in the first half of 2026, about $13.9 million a quarter, slightly less than the $30.1 million used in the first half of 2025.
• Loss per share shrank 35% to $0.40, but the dollar loss shrank only 5.5%. Most of the per-share improvement comes from having about 45% more shares outstanding, which spreads the same loss over more owners.

The quarter in numbers

All figures are for the three months ended June 30 unless noted. Money in millions of US dollars.

"Cash runway" is how long the company's existing money lasts at its planned spending before it has to raise more. For a company with no sales it matters more than profit, because running out of runway usually means selling new shares at whatever price the market offers.

Where the research money went

R&D is almost all of Contineum's spending, and the mix inside it shifted sharply. The filing breaks out direct costs by drug program:

According to the 10-Q, contract research costs (fees paid to outside firms that run trials) fell $2.0 million. Inside that, costs for the completed VISTA Phase 2 trial of PIPE-307 in relapsing multiple sclerosis fell $2.1 million, the PIPE-791 chronic pain trial cost $0.9 million less as it wound down, and a finished PIPE-791 brain-imaging trial cost $0.4 million less. Against that, the new IPF trial added $1.4 million. Toxicology study spending, mostly for PIPE-791 and CTX-343, fell another $0.8 million. Stock-based compensation, staff, facilities and equipment pushed the other way by about $1.5 million combined.

So the 10% drop in R&D is a timing effect: trials ending before the big new one is fully enrolled. It is not a sign that spending has peaked. Management's own wording in the filing is that it expects R&D expenses to "increase substantially".

What the headline numbers hide

• The cash burn is lower than the loss, partly because of stock pay. Net loss for the first half was $29.6 million, but cash used in operations was $27.8 million. The biggest non-cash item is stock-based compensation, which rose to $7.7 million in the half from $5.0 million a year earlier. It does not drain cash, but it is a real cost to shareholders, paid in new shares instead of dollars. It also explains almost all of the G&A increase: of the $0.9 million rise in the quarter, $0.7 million was stock compensation.
• The runway guidance assumes spending goes up. At the first half's pace of about $4.6 million of operating cash a month, $236.6 million would last more than four years. Management guides to about three years (mid-2029). The gap is the planned ramp of the IPF trial, which had more than 55 sites open in eight countries by the end of July, plus any added programs. The guidance looks conservative compared with the current burn, but the current burn understates what a fully enrolling global trial costs.
• Interest income is cushioning the loss. The company earned $2.3 million in interest in the quarter, covering about 13% of operating expenses. That shrinks as the cash is spent, and would also shrink if interest rates fall.
• The per-share loss improvement is mostly dilution. Weighted shares rose from 25.9 million to 37.5 million because of the December 2025 offering (8.1 million shares at $12.25) and 3.2 million shares sold in 2025 through an "at-the-market" program, which lets a company sell shares into the market gradually. In March 2026 the company set up room to sell up to another $100.0 million that way. It sold none in the first half of 2026, but that capacity is there.
• A small accounting credit on PIPE-307. Direct PIPE-307 costs came in at negative $0.3 million in the quarter (an adjustment of earlier accruals), which flatters R&D slightly. It is too small to change the picture.
• A restructuring with no cost shown yet. On July 30 the company said it had streamlined its discovery research to focus on inflammatory and fibrotic diseases, with a "limited workforce reduction" that included the departure of its Chief Scientific Officer, Daniel Lorrain. The Q2 filing shows no severance charge, so any one-off cost would land in Q3.

After the quarter: the PIPE-307 depression trial missed

On September 14, 2026, Contineum reported that J&J's MOONLIGHT-1 trial of PIPE-307 (J&J calls it JNJ-5120) in 107 adults with major depressive disorder did not meet its primary endpoint, which was improvement on a standard depression rating scale at day 5 versus placebo. The drug was well tolerated with no new safety signals, and J&J is still analysing exploratory endpoints before deciding next steps.

This matters for what Contineum might earn, not for what it spends. Under the 2023 license, J&J pays for PIPE-307 development; Contineum already received $50.0 million upfront and is eligible for about $1.0 billion in further milestone payments plus royalties in the low-double-digit to high-teen percent range on any sales. A failed Phase 2 makes those future payments less likely, and J&J alone decides whether to continue. It also leaves Contineum more dependent on a single asset, PIPE-791.

Takeaway: Contineum's finances are in decent shape for a company with no sales, about three years of guided runway and a burn that has not yet ramped up, but after September's failed PIPE-307 depression trial the company's prospects rest almost entirely on PIPE-791, and in particular on the IPF trial that has only just started enrolling.

What to watch next

• PROPEL-IPF enrollment pace. The 26-week trial of once-daily oral PIPE-791 measures change in forced vital capacity (FVC, how much air a patient can forcefully exhale, the standard measure of lung function in IPF). Management ties its runway to the trial finishing roughly a year before mid-2029, which implies results around mid-2028. Any slip in enrollment eats into that cushion.
• J&J's decision on PIPE-307. Whether J&J continues in depression or another indication, or hands the rights back, decides whether the milestone payments are still realistic.
• Spending in the Q3 report. Look for R&D starting to rise as IPF trial costs build, any severance cost from the July workforce reduction, and whether management keeps the mid-2029 runway guidance after the MOONLIGHT-1 result.
• Share sales. With $100.0 million of at-the-market capacity unused, any sales would extend the runway at the cost of further dilution.
• Chronic pain. PIPE-791's Phase 1b chronic pain trial met its safety goal in April 2026 and showed numerically greater pain improvement than placebo, which management says supports further study. A decision to fund a larger pain trial would be the clearest sign of whether the company plans to spend beyond IPF.

Our read: the quarter itself was uneventful and clean, with spending moving for explainable timing reasons. The investment case now hinges on PIPE-791 in IPF, and the next two to three years are a cash-funded wait for that data.